Genome & Company, a global biopharmaceutical company, will participate in the “Bio International Convention” (BIO 2023) from June 5 to 8 in Boston, USA.
BIO 2023 USA is a global bio event organized annually by the Biotechnology Innovation Organization and will be held in Boston, USA this year.
At this event, Genome & Company plans to strengthen business partnerships with global pharmaceutical companies through meetings, discussing the development of new drug candidates. The company will provide updates on the development of GEN-001, a microbiome immuno-oncology drug, and GENA-104 and GENA-111, new target immuno-oncology drugs, and explore opportunities for strategic partnerships, including technology transfer and joint development.
Genome & Company’s microbiome field subsidiaries, List Biological Laboratories, Inc., List Biotherapeutics, Inc., and Scioto Biosciences, Inc. will also participate in BIO 2023 USA. They are planning to hold a meeting with a variety of companies to expand production orders. In particular, Scioto will hold a partnering meeting ahead of the start of the phase II clinical trial of SB-121, a treatment for autism spectrum disorder (ASD) based on the microbiome.
Bae Ji-soo, CEO of Genome & Company, said, “We hired Hong Yoo-seok, general manager, to strengthen the commercialization of new drug candidates and our overseas business. This way, we plan to strengthen the partnering meetings with global pharmaceutical companies in the future. And the company and all our subsidiaries will actively participate in various meetings to grow into a global drug developer.”
Genome & Company, founded in 2015 at Pangyo Techno Valley, is currently conducting phase II clinical trials for GEN-001, an immuno-oncology microbiome treatment for gastric cancer and biliary tract cancer, and GENA-111, an ADC candidate, in collaboration with global pharmaceutical company Debiopharm.
For inquiries and connections with Korean tech companies mentioned in this article, contact us at [email protected]. We’re here to facilitate valuable partnerships.
- Pangyo Techno Valley, a Bridgehead for Global Expansion of the Korean Bio Industry
- Lee Won-jun and Park Kyu-tae, co-founders of Avalve, a startup with the AI Smart Farm Solution, selected by Forbes as one of the most influential leaders under the age of 30 in Asia
- Entertech startup VWX Labs secures additional seed Investment from 1Billion Partners for its artist career platform ‘Talented’
- Hanwha Aerospace Invests in US Startup “Forge Nano” for Battery Life Extension Technology